Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

Turnbull, F; Neal, B; Algert, C; Chalmers, J; Woodward, M; MacMahon, S; MacMahon, S; Baigent, C; Cutler, J; Fagard, Robert; Neal, B; Whelton, P; Yusuf, Satara; Algert, C; Chalmers, J; Chapman, N; MacMahon, S; Neal, B; Turnbull, F; Woodward, M; Agodoa, L; Baigent, C; Black, H; Boissel, JP; Brenner, B; Brown, M; Bulpitt, C; Byington, R; Chalmers, J; Collins, R; Cutler, J; Dahlof, B; Davis, B; Dens, Joseph; Estacio, R; Fagard, Robert; Fox, K; Hansson, L; Holman, R; Hunsicker, L; Kostis, J; Kuramoto, K; Lewis, E; Lindholm, L; Lubsen, J; MacMahon, S; Malacco, E; Mancia, G; Neal, B; Pepine, C; Pfeffer, M; Pitt, B; Poole-Wilson, P; Remuzzi, G; Rodgers, A; Ruggenenti, P; Schrier, R; Sever, P; Sleight, P; Staessen, Jan A; Tco, K; Turner, R; Whelton, P; Wing, L; Yui, Y; Yusuf, Satara; Zanchetti, A

doi:10.1016/s0140-6736(03)14739-3

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

Author:

Turnbull, F

Neal, B ; Algert, C ; Chalmers, J ; Woodward, M ; MacMahon, S ; MacMahon, S ; Baigent, C ; Cutler, J ; Fagard, Robert ; Neal, B ; Whelton, P ; Yusuf, Satara ; Algert, C ; Chalmers, J ; Chapman, N ; MacMahon, S ; Neal, B ; Turnbull, F ; Woodward, M ; Agodoa, L ; Baigent, C ; Black, H ; Boissel, JP ; Brenner, B ; Brown, M ; Bulpitt, C ; Byington, R ; Chalmers, J ; Collins, R ; Cutler, J ; Dahlof, B ; Davis, B ; Dens, Joseph ; Estacio, R ; Fagard, Robert ; Fox, K ; Hansson, L ; Holman, R ; Hunsicker, L ; Kostis, J ; Kuramoto, K ; Lewis, E ; Lindholm, L ; Lubsen, J ; MacMahon, S ; Malacco, E ; Mancia, G ; Neal, B ; Pepine, C ; Pfeffer, M ; Pitt, B ; Poole-Wilson, P ; Remuzzi, G ; Rodgers, A ; Ruggenenti, P ; Schrier, R ; Sever, P ; Sleight, P ; Staessen, Jan A ; Tco, K ; Turner, R ; Whelton, P ; Wing, L ; Yui, Y ; Yusuf, Satara ; Zanchetti, A

Keywords:

converting-enzyme-inhibitor, coronary heart-disease, isolated systolic hypertension, calcium-channel blocker, double-blind, antihypertensive therapies, microvascular complications, outcomes, mortality, morbidity, Science & Technology, Life Sciences & Biomedicine, Medicine, General & Internal, General & Internal Medicine, CONVERTING-ENZYME-INHIBITORS, DOUBLE-BLIND, ANTIHYPERTENSIVE THERAPIES, 1ST-LINE AGENTS, HEART-FAILURE, HYPERTENSION, MORBIDITY, MORTALITY, OUTCOMES, CORONARY, Adrenergic beta-Antagonists, Aged, Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Calcium Channel Blockers, Cardiovascular Diseases, Diuretics, Female, Heart Failure, Humans, Hypertension, Male, Middle Aged, Placebos, Prospective Studies, Randomized Controlled Trials as Topic, Risk Assessment, Treatment Outcome, Blood Pressure Lowering Treatment Trialists' Collaboration, 11 Medical and Health Sciences, 32 Biomedical and clinical sciences, 42 Health sciences

Abstract:

Background The benefits of reducing blood pressure on the risks of major cardiovascular disease are well established, but uncertainty remains about the comparative effects of different blood-pressure-lowering regimens. We aimed to estimate effects of strategies based on different drug classes (angiotensin-converting-enzyme [ACE] inhibitors, calcium antagonists, angiotensin-receptor blockers [ARBs], and diuretics or P blockers) or those targeting different blood pressure goals, on the risks of major cardiovascular events and death.